Abstract: The present disclosure provides methods related to the purification of a biologic. In particular, the present disclosure methods for purifying a biologic using a multifunctional chromatography medium comprising porous beads or particles having a defined pore diameter distribution and one or more ligands conjugated to the surface of the pores capable of removing process-related impurities and product-related impurities from a target biologic.

Abstract: The disclosure provides a novel flush method using a recovery flush technique that minimizes yield losses due to inadequate flushing and prevents or reduces dilution of a target protein during a recovery flush.

Abstract: The present invention provides kappa opioid receptor peptide agonists, methods for preparing these compounds, compositions comprising these kappa opioid receptor peptide agonists, and methods of using the kappa opioid receptor peptide agonists to treat pain or other conditions.

Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.

Abstract: A small peptide drug with AR protein degrading capacity for prostate cancer-specific treatment.

Abstract: The present invention provides mutant RSV F molecules, such as those that can be, or are stabilized, in a pre-fusion conformation by the introduction of one or more DT cross-links. The present invention also provides methods of making such mutant RSV F molecules, compositions comprising such mutant RSV F molecules, and methods of use of such mutant RSV F molecules, for example in vaccination methods, therapeutic methods, and antibody production methods.

Abstract: The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.

Abstract: The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.

Abstract: Computational systems and methods are described for identifying new type-II bacteriocins using a systemic consensus formula and other related criteria. Newly identified type-II bacteriocin peptides are tested experimentally and show potent microbiocidal activities.

Abstract: The present invention includes light-controlled and light-independent neurotoxin systems and methods for using such neurotoxin systems for rapidly and locally silencing distinct populations of neurons.

Abstract: Compositions and methods for editing an endogenous NAC genes in plants are provided, for the improvement of traits of agronomic or commercial importance. Modifications of expression and activity of NAC genes are described, including editing endogenous NAC gene functional motifs and knocking out NAC gene function.

Abstract: The invention relates to a mutant of a small molecule chaperone protein MOG1-encoding gene and a use thereof, belonging to the technical field of biomedicine. The invention uses a mutant of a small molecule chaperone protein MOG1-encoding gene and a mutant of a small molecule chaperone protein MOG to prepare a use for treatment of diseases such as Brugda syndrome, arrhythmia, dilated cardiomyopathy, or heart failure. The mutant of the invention is more effective than a wild-type MOG1 in enhancing myocardial sodium current.

Abstract: Methods and compositions for nuclear delivery and transcriptional repression employ a cell-penetrant MeCP2 fusion protein.

Abstract: The present invention provides a transcription factor NCgl0581 mutant and use thereof in L-serine detection, belonging to the technical field of biological detection. According to the present invention, key binding sites of the transcription factor NCgl0581 with L-serine are obtained through molecular docking, and further model analysis and virtual screening are carried out to obtain an L-serine biosensor mutant NCgl0581E136P. Experiments show that the biosensor constructed based on the mutant NCgl0581E136P can respond to 25 mM serine, which is half of the response concentration before the mutation. The present invention reduces the detection limit of the biosensor through mutation, lays a foundation for the detection of low-concentration L-serine, and has good application value and prospect.

Abstract: The present invention relates to a synthetic peptide analog of the Preimplantation factor (PIF) peptide with a sequence length of maximum 20 amino acids consisting in the sequence Xaa1 Xaa2 R3 I4 K5 P6 Xaa7-20 (SEQ ID No1): wherein Xaa can be any amino acid for use in the treatment and/or prevention of Retinitis Pigmentosa and a pharmaceutical composition comprising one or more synthetic peptide analog from PIF peptides and one or more acceptable carriers.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Methods and compositions including granulin/epithelin modules (GEMs) or combinations thereof suitable for treating neurodegenerative diseases. Also disclosed are methods of treatment of neurodegenerative diseases, such as methods of administering therapeutic recombinant GEM proteins or gene therapies for delivering recombinant GEM gene products.

Abstract: The present invention resides in the discovery that the specific interaction between vascular endothelial growth factor (VEGF) and integrin, especially integrin ?v?3, is involved in cellular signaling mediated by VEGF-integrin, such as angiogenesis and inflammatory responses. Thus, this invention provides for a novel method for inhibiting angiogenesis or inflammation induced by integrin signaling by using an inhibitor of VEGF-integrin binding, such as a dominant negative mutant of VEGF without integrin-binding capability. A method for identifying inhibitors of VEGF-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, host cells, and corresponding compositions for inhibiting VEGF-integrin signaling.

Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.

Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.

Abstract: The present invention relates to an VHH masked cytokines, comprising an IL-2 polypeptide, an anti-IL-2 VHH masking moiety and a proteolytically cleavable peptide. The anti-IL-2 VHH masking moiety masks IL-2 reducing or preventing binding of the cytokine or functional fragment thereof to its cognate receptor. Upon proteolytic cleavage at a target site, the IL-2 becomes activated, which renders it capable or more capable of binding to its cognate receptor.

Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Abstract: Modified polypeptides comprising an amino acid sequence having a lysine or derivative thereof functionalized at N6 with a seryl or threonyl group are disclosed, as are bioconjugates comprising the modified polypeptides, and methods for making the bioconjugates.

Abstract: Provided herein are novel chimeric polypeptides that bind an antigenic peptide (e.g., a viral antigen or a tumor-associated antigen) and activate the endogenous phagocytic signaling pathway. Also provided are compositions and methods useful for producing such chimeric polypeptides, nucleic acids encoding same, phagocytic cells that have been modified to express such chimeric polypeptides, as well as methods for the treatment of various disorders, such as viral infections or cancers.

Abstract: The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide, an epitope-presenting peptide, and class I MHC polypeptides. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.

Abstract: Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction), increased stability, and/or the ability to form multimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. In various embodiments, such polypeptides may be used to treat companion animals, such as canines, felines, and equines.

Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions and pharmaceutical formulations comprising the polypeptides and polynucleotides of the disclosure and methods of using and producing same are also disclosed.

Abstract: The present disclosure provides a method of treating hemophilia A in a human subject in need thereof comprising administering to the subject a chimeric protein comprising (i) a factor VIII (FVIII) protein and (ii) a von Willebrand factor (VWF) fragment comprising a D? domain of VWF and a D3 domain of VWF.

Abstract: This disclosure relates to development of biocompatible and resorbable type II collagen fibers for medical applications. Its characteristics and methods of preparation are also disclosed.

Abstract: This disclosure provides an alpha-1 antitrypsin (AAT) polypeptide as defined herein. Also provided herein are pharmaceutical compositions comprising the polypeptide, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid, cells, and methods of producing the AAT polypeptide and method of using the AAT polypeptide in therapy.

Abstract: A peptide, polypeptide, protein, DNA construct, vector, composition, or fusion protein for the treatment of a condition, such as cancer, and a method of treating the condition (cancer) using the peptide, polypeptide, protein, or composition, are disclosed. The polypeptide or composition includes a fusion protein comprising a modified cystatin peptide.

Abstract: The present invention relates to a novel antigen peptide and, more specifically, the antigen peptide is for preparing an antibody capable of specifically detecting formyl-methionine. It has been identified that an antibody prepared using an antigen peptide for the preparation of a formyl-methionine-specific antibody, according to the present invention, has excellent antigen-binding ability at peptide and protein levels and has excellent antigen-binding ability even under a condition in which intracellular formylated protein expression changes. Therefore, an antigen peptide of the present invention can be effectively used in the preparation of antibodies universally recognizing peptides and proteins having formyl-methionine.

Abstract: A single-domain antibody or an antigen-binding fragment thereof for neutralizing canine parvovirus (CPV) including a heavy chain encompassing a variable region. The variable region includes three complementarity-determining regions (CDRs): CDR1, CDR2, and CDR3. The three complementarity-determining regions CDR1, CDR2, and CDR3 have a combination of different amino acid sequences. The antibodies effectively prevent CPV from infecting F81 cells, exhibiting high binding affinity and specificity, and significant neutralizing activity against CPV. Consequently, the antibody sequences and expression vectors of the disclosure are valuable tools for various applications in CPV epitope identification, prevention, treatment, and diagnosis.

Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.

Abstract: Provided in the present disclosure is an antibody or fragment thereof against a human growth and differentiation factor 15 (GDF15). Further provided in the present disclosure is the use of the antibody or fragment thereof in the preparation of a drug for treating diseases or conditions. The antibody or fragment thereof provided in the present disclosure can bind to human GDF15 with high affinity and specificity, blocks the interaction of GDF15 with receptor GFRAL thereof, and has a longer half-life period in vivo in comparison with antibodies of the same kind.

Abstract: Herein are provided isolated, humanized, anti-S100A4 antibody molecules and methods of producing said antibodies. Also provided are nucleic acids, vectors, isolated host cells and pharmaceutical compositions containing the antibody, and methods of treatment comprising administering said antibody.

Abstract: Methods of treating or preventing alcoholic liver disease are disclosed, the methods comprising administering to a subject a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling.

Abstract: The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting and administering to a subject in need thereof a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor and a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor. In certain embodiments, the IL-4/IL-13 pathway inhibitor enhances the anti-tumor efficacy of PD-1 blockade.

Abstract: The present invention generally relates to improved Protease-activatable antigen-binding molecules that comprise an anti-idiotype-binding moiety which reversibly masks a CD3 antigen binding moiety of the molecule. Furthermore, the invention relates to novel Protease-cleavable peptide linkers and their used in such Protease-activatable antigen-binding molecules. In addition, the present invention relates to polynucleotides encoding such Protease-activated T cell binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the Protease-activated T cell binding molecules of the invention, and to methods of using the same, e.g., in the treatment of disease.

Abstract: Methods, agents, and compositions for promoting milk production in a mammal are provided. Agents useful for promoting milk production may include an agent that inhibits NOTCH4 activity. The agent may inhibit NOTCH4 activity by binding to ROBO2 and/or by binding to NOTCH4. The agent may inhibit NOTCH4 by competing with ROBO1 for binding to ROBO2, thereby making ROBO1 available to inhibit NOTCH4 activity. The agent may be a soluble ROBO1 extracellular domain or an anti-NOTCH4 antibody that inhibits NOTCH4 activity. The agent may be an RNAi construct that inhibits expression of NOTCH4 or an RNAi construct that inhibits expression of ROBO2. Also provided herein are transgenic mammals genetically modified for expression of a soluble ROBO1 extracellular domain; inhibition of expression of ROBO2; and/or inhibition of expression of NOTCH4. Methods for promoting milk production in such transgenic mammals by administering one or more of the agents disclosed herein are also provided.

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: Disclosed herein are anti-immunoglobulin-like transcript-3 (ILT3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract: The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Abstract: Anti-V?17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.

Abstract: Provided in the present invention is an antibody or an antigen binding protein thereof. The antibody or the antigen binding protein thereof can specifically bind to human CD3 or human GPRC5D protein or MUC16, or specifically bind to human CD3 and a second antigen. Further provided in the present invention are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody, a host cell and a preparation method therefor. Also provided in the present invention is a diagnosis and treatment method using the antibody of the invention.

Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: Compositions including solid forms of polypeptides such as crystalline antibodies, and related methods, are generally described. The compositions may include carriers such as hydrogels that at least partially encapsulate the solid form of the polypeptides (e.g., crystals, amorphous solids). Encapsulation with certain of the materials described may result in compositions containing relatively high loadings of polypeptides while in some instances retaining structural and functional properties of the polypeptides useful for certain types of administration to subjects (e.g., for prophylactic or therapeutic applications). In some instances, compositions having relatively low dynamic viscosities while having relatively high polypeptide loadings are provided.